Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-cell Lymphoma Intervention:   Biological: RC19D2 cell injection Sponsor:   Beijing Yongtai Ruike Biotechnology Company Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials